Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
David Dalke
Advertisement
Articles by David Dalke
Advertisement
Latest Updated Articles
New Patent-Defense Path for PharmaPublished: October 1st 2014 | Updated: November 17th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
FDA Approves Hernexeos Under National Priority Voucher Program
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Leading in the Psychedelic Space: Q&A with Tarek Rabah
5